Cover Image

Comparative Efficacy of Single Pill Combinations of Azilsartan Medoxomil/Chlorthalidone and Losartan/Hydrochlorothiazide in Patients with Hypertension and Heart Failure with Preserved Ejection Fraction

Aim. To study the effects of azilsartan medoxomil/chlorthalidone (AZM/CTD) and losartan/hydrochlorothiazide (LOS/HCT) combinations for NTproBNP levels, 6-minute walk test results, hydration status along with their antihypertensive efficacy according to clinical and 24-hour blood pressure in patients...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zh. D. Kobalava (Author), A. F. Safarova (Author), Kh. M. Gudieva (Author), M. A. Markova (Author), A. E. Petrosyan (Author)
Format:	Book
Published:	Столичная издательская компания, 2022-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Azilsartan/chlorthalidone combination therapy for blood pressure control
by: Cheng JW
Published: (2013)

Chlorthalidone, not hydrochlorothiazide, is the right diuretic for comparison
by: Ravi Tejraj Mehta, et al.
Published: (2018)

Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients
by: Lakshmi Manasa S. Chekka, et al.
Published: (2022)

New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
by: Volpe M, et al.
Published: (2012)

Delaminating Intramyocardial Hematoma in Patients with Heart Failure with Reduced Ejection Fraction: а Series of Clinical Cases
by: A. F. Safarova, et al.
Published: (2023)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
by: Attila Juhasz, et al.
Published: (2018)

Efficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes
by: A. M. Kochergina, et al.
Published: (2023)

ATRIAL FIBRILLATION AND ARTERIAL HYPERTENSION: GENDER DIFFERENCES OF VENTRICULOATRIAL REMODELING WITH PRESERVED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2017)

ANTIHYPERTENSIVE TREATMENT WITH COMBINED DRUG OF LOSARTAN AND HYDROCHLOROTHIAZIDE
by: R. M. Linchak, et al.
Published: (2016)

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
by: Punzi HA
Published: (2011)

Optimized and Validated RP-UPLC Method for the Determination of Losartan Potassium and Chlorthalidone in Pharmaceutical Formulations
by: Tadiboyina Sirisha, et al.
Published: (2015)

Hydrochlorothiazide/Losartan Potassium Tablet Prepared by Direct Compression
by: Qiuhua Luo, et al.
Published: (2022)

An elderly female with pemphigus foliaceus possibly induced by losartan/hydrochlorothiazide
by: Wei-En Wang, et al.
Published: (2021)

In silico assessment of chronic toxicity of a combination drug namely 'Olmesartan medoxomil and Hydrochlorothiazide', marketed in Bangladesh
by: Matrika Saha Roy, et al.
Published: (2021)

Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
by: Mac Arturo Murillo-Fernández, et al.
Published: (2022)

Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability: In Vitro and Ex Vivo Evaluation
by: Girish Kumar, et al.
Published: (2022)

Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
by: Mengxi Wang, et al.
Published: (2021)

THE ROLE OF FACTORS AFFECTING THE FORMATION OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION
by: M. V. Kurkina, et al.
Published: (2017)

Antihypertensive and Target-Organ Protective Properties of Telmisartan and Hydrochlorothiazide Single-Pill Combination
by: O. D. Ostroumova, et al.
Published: (2019)

A case of papuloerythroderma of Ofuji possibly associated with a combination drug of losartan potassium/hydrochlorothiazide
by: Gyohei Egawa, et al.
Published: (2022)

Spectrophotometric method for simultaneous estimation of atenolol in combination with losartan potassium and hydrochlorothiazide in bulk and tablet formulation
by: Sanjay Bari, et al.
Published: (2010)

Pediatric heart failure with preserved ejection fraction, a review
by: Sophie Quennelle, et al.
Published: (2023)

ACHIEVEMENT OF TARGET BLOOD PRESSURE LEVEL IN PATIENTS WITH ARTERIAL HYPERTENSION OF 2-3 DEGREE WITH FIXED COMBINATION OF ENALAPRIL OR LOSARTAN WITH HYDROCHLOROTHIAZIDE
by: A. A. Kudryavtsev, et al.
Published: (2016)

Association Between Hyperaldosteronemia and Electrophysiological Myocardial Activity in Heart Failure with Preserved Ejection Fraction
by: A. N. Shevelok
Published: (2020)

Tailoring Chlorthalidone Aqueous Solubility by Cocrystallization: Stability and Dissolution Behavior of a Novel Chlorthalidone-Caffeine Cocrystal
by: Christian Rodríguez-Ruiz, et al.
Published: (2022)

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
by: Andrew J.S. Coats, et al.
Published: (2024)

NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
by: James P. Teuber, et al.
Published: (2022)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
by: Ajmer Singh, et al.
Published: (2018)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018)

Dynamics of Vascular Stiffness and Endothelial Function in Combination Therapy of Heart Failure with Preserved Ejection Fraction
by: Z. M. Akhilgova, et al.
Published: (2020)

Evaluation of claims‐based computable phenotypes to identify heart failure patients with preserved ejection fraction
by: Sarah S. Cohen, et al.
Published: (2020)

DIASTOLIC LEFT VENTRICULAR DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION IN ELDERLY
by: CALENICI Oleg, et al.
Published: (2022)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
by: Artem Ovchinnikov, et al.
Published: (2022)

Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?
by: V. D. Zakiev, et al.
Published: (2023)

Optimising TRIUMPH with 6·25 mg chlorthalidone
by: Anil Pareek, et al.
Published: (2020)

Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill
by: Michel Burnier
Published: (2010)

Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024)

Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction
by: Alexandrina Campos-Martins, et al.
Published: (2021)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023)